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Abstract
Scaffold-based cancer cell culture techniques have been gaining prominence especially in
the last two decades. These techniques can potentially overcome some of the limitations of
current three-dimensional cell culture methods, such as uneven cell distribution, inadequate
nutrient diffusion, and uncontrollable size of cell aggregates. Porous scaffolds can provide a
convenient support for cell attachment, proliferation and migration, and also allows diffusion
of oxygen, nutrients and waste. In this paper, a comparative study was done on porous poly
(lactic-co-glycolic acid) (PLGA) microparticles prepared using three porogens—gelatin,
sodium bicarbonate (SBC) or novel poly N-isopropylacrylamide [PNIPAAm] particles, as
substrates for lung cancer cell culture. These fibronectin-coated, stable particles (19–
42 μm) supported A549 cell attachment at an optimal cell seeding density of 250,000 cells/
mg of particles. PLGA-SBC porous particles had comparatively larger, more interconnected
pores, and favored greater cell proliferation up to 9 days than their counterparts. This indi-
cates that pore diameters and interconnectivity have direct implications on scaffold-based
cell culture compared to substrates with minimally interconnected pores (PLGA-gelatin) or
pores of uniform sizes (PLGA-PMPs). Therefore, PLGA-SBC-based tumor models were
chosen for preliminary drug screening studies. The greater drug resistance observed in the
lung cancer cells grown on porous particles compared to conventional cell monolayers
agrees with previous literature, and indicates that the PLGA-SBC porous microparticle sub-
strates are promising for in vitro tumor or tissue development.
Introduction
The practice of tissue and cell culture has been in existence as early as 1885 when Wilhelm
Roux demonstrated that the medullary plate of a chick embryo can be maintained on glass
plates with warm saline solution [1, 2]. Since then, cells have been traditionally cultured in
vitro on two-dimensional (2D) polystyrene or glass surfaces. 2D cell culture models are still in
use in pharmacology today for drug screening and cytocompatibility studies. However, these
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conventional 2D systems differ from in vivo tissues in cell surface receptor expression, extra-
cellular matrix synthesis, cell density, and metabolic functions [3]. They are also unable to
develop hypoxia or mimic the cell arrangement seen in different parts of the tissues and
tumors [4]. Further, studies have shown that tumor cell monolayers grown on tissue culture
plates develop a non-natural morphology, which could be a major factor affecting their
responses to drugs [5]. According to recent reports, the promising effects of therapeutic agents
in in vitro 2D cell culture systems have not translated into successful results in animals, and in
humans. Only about 5% of the chemotherapeutic agents that showed promising preclinical
activity have demonstrated significant therapeutic efficacy in phase III clinical trials [6]. There-
fore, there is a vital need for an in vitro cell culture model that mimics in vivo tissues more
closely, for cancer drug screening and personalized medicine applications.
Several platforms for 3D cell culture have being investigated today and have demonstrated
potential to recreate cancer microenvironment and drug responses similar to in vivo condi-
tions. Scaffold-free methods such as spheroids formed by self-assembly of cells is one of the
most common and versatile methods of culturing cells in 3D [7]. Spheroids can recapitulate
the 3D architecture of tissues and mimic the physiological barriers that affects drug delivery in
vivo. However, the main challenge in using spheroids as efficacy testing models is their inabil-
ity to form and maintain spheroids of uniform diameters [8]. Although this limitation can be
overcome to some extent using microwells, specialized methods and facilities may be required
for microwell generation. Furthermore, microwells are not suitable for long-term culture as
cells can outgrow the space available in the wells [9]. Conventional methods including hanging
drop are able to define the sizes of spheroids, but these procedures are extremely labor inten-
sive and time consuming [10]. Magnetic levitation has been studied to form complex in vitro
cell structures, however premature release of the magnetic micro/nanoparticles had raised tox-
icity concerns due to which approaches for improved magnet-based cell assembly are being
investigated [11]. Another approach employs hydrogels embedded with tumor cells, but the
spatial distribution of cells within the gels are not uniform resulting in variations between
batches. Similar challenge is posed by large polymeric scaffolds where cells outside would be
exposed to nutrients and oxygen, while cells within the scaffold may become necrotic quickly
due to limited availability of resources essential for their growth [12, 13]. Bioprinting has been
gaining prominence as it can provide spatial control for in vitro model development [14], how-
ever this method requires specialized equipment such as bioprinters and bioreactors which
may raise the cost and reduce feasibility for high throughput screening [9]. In consideration of
these challenges, biodegradable microparticles (MPs) offers a better alternative both to 2D and
existing scaffold-free methods, as they provide large surface area suitable for cell attachment
and long-term culture for tumor ECM deposition. They can also be used to generate organized
cell arrangements in vitro according to the disease or tissue being studied, which is an advan-
tage over 2D and several scaffold-free cell models [15]. Several natural (alginate [16], collagen
[17], hyaluronic acid [18], basement membrane matrix [19]) and synthetic (poly(lactic acid-
co-glycolic acid) [3], polycaprolactone [18], polyethylene glycol [20], polylactic acid [21]) poly-
mer-based particles have been utilized to develop in vitro cancer models for various cancer
studies.
In tissue engineered scaffolds and microparticles, porosity is an important parameter to be
considered, in order to ensure high levels of cell density and viability by facilitating effective
transfer of nutrients/oxygen and metabolic wastes during the culture [22]. Porous scaffolds
tend to resemble the arrangement of the extracellular matrix, which facilitates cell attachment
and proliferation [23]. Such porous microspheres have also shown to have great potential as
injectable cell carriers for tissue engineering and regenerative purposes [24, 25] as well as a
scaffold for tumor modelling [23, 26]. Depending on the porogen incorporated into particles
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the porosity can be enhanced or tuned for the required application. Although porous poly-
meric microparticles have been characterized before for various tissue engineering applica-
tions, there have been no comparative studies to the authors’ knowledge on the effects of
different porogens on pore diameter and distribution within microparticles, and how this
influences the development of tissue engineered tumors and tissues. Therefore, the goal of this
work is to develop and screen porous microparticles prepared using different porogens and
choose the optimum substrate for scaffold-based lung tumor culture in vitro.
When compared with other types of cancers, lung cancer is by far the leading cause of
death, regardless of gender or ethnicity [27]. Although diagnosis at early stage of lung cancer
offers a favorable prognosis, most patients (~75%) have advanced disease at the time of diag-
nosis [28]. Significant research into the oncological management of late stage lung cancer have
occurred in recent years, which have been supported by promising in vitro data. However
these have not translated into successful clinical trials and lung cancer survival rate remains
poor [28]. The chief issue here is the lack of preclinical models capable of predicting the behav-
ior and effect of targeted therapies in humans [29]. So our aim is to facilitate such translation
by developing methods for bench-top lung tumor culture using porous microparticles, for
anti-cancer drug testing and to study cancer progression.
To develop the in vitro model, PLGA—an FDA-approved biocompatible and biodegradable
polymer—was used to form the particles. We compared porous PLGA microparticles devel-
oped using three porogens namely gelatin, sodium bicarbonate (SBC) or PNIPAAm (poly (N-
isopropylacrylamide)) based particles (PMPs). Gelatin has been widely employed as sacrificial
material to template vascular networks or cellular compartments in scaffolds [30, 31]. In this
case, pore diameter is determined by the size of gelatin/water emulsion formed during synthe-
sis of PLGA particles. These water droplets when dispersed in the oil phase can gradually coa-
lesce over time, leading to an increase in size for the droplets [32]. Therefore, controlled pore
formation is difficult with this method. SBC on other hand is a gas porogen, which creates
pores in the substrate by generating gas bubbles (carbon dioxide) in mildly acidic environment
[33]. These gas bubbles trapped within the particles can be in contact with each other, leading
to the formation of a highly interconnected pore structure in the particles [34]. Lastly, we
introduce an innovative method to control the pore diameter using PMPs (diameter ~1μm)
developed previously by our lab, as porogens [35]. Due to the temperature responsive proper-
ties of PNIPA at its lower critical solution temperature (LCST) [35, 36], PMPs will shrink and
diffuse out of the PLGA, leaving behind a uniformly porous matrix. The use of temperature-
sensitive particles as porogens to develop porous polymeric substrates for cell attachment has
not been reported before.
Experimental section
All chemicals, unless mentioned specifically, were purchased from Sigma-Aldrich (St. Louis,
MO) and used without further purification. No human participants or vertebrate animals
were used in this research. Immortalized A549 lung adenocarcinoma cell line was purchased
from ATCC (CCL-185) for in vitro cell culture experiments. The cell culture protocols were
approved by the Institutional Review Board (IRB) at the University of Texas at Arlington.
Preparation of PLGA MPs
All polymeric MPs were prepared by a standard double emulsion method. The concentrations
of the components used in each MP preparation were optimized so that the final particles will
have relatively similar diameters for better comparison. The preparation technique for gelatin
porogen-based particles was modified from a previously published work by Huang et al [37].
Porous microparticles for lung tumor culture
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In brief, 37.5 mg of gelatin (extracted from bovine skin, type B) dispersed in 60 ml of 1% (w/v)
Polyvinyl alcohol (PVA) was added dropwise to 5 ml of 2% (w/v) PLGA (Lakeshore Biomateri-
als, Birmingham, AL) in dichloromethane and vortexed. The resulting emulsion was added to
1% (w/v) PVA solution placed in ice water bath. Following overnight stirring to evaporate the
organic solvent, gelatin leaching was done by keeping the particle suspension in a warm water
bath at 45˚C under gentle stirring for 4 hours. The porous particles were then isolated by wash-
ing three times with water, followed by centrifugation at 4000 rpm for 5 mins and lyophiliza-
tion. Non-porous (control) PLGA microspheres were also prepared by the same method,
excluding the gelatin addition and leaching.
The SBC porogen-based particles were prepared by modifying the protocol of Ke et al. [38].
Briefly, 500 μl of 1% (w/v) SBC solution was added dropwise to 2 ml of 5% (w/v) PLGA solu-
tion in DCM. This emulsion was then added dropwise to 60 ml of 0.1% (w/v) PVA solution
and gently stirred overnight. SBC leaching was done by centrifuging the obtained particles in
PBS solution at a pH of 3–4 at a speed of 1500 rpm for 30 min. Subsequently, the particles were
washed twice in DI water, isolated by centrifugation (1500 rpm, 30 min) and lyophilized to
obtain porous PLGA microspheres.
To prepare the PMPs porogens, first the PMPs were prepared by free radical polymerization
based on protocol previously developed by our group [35, 36]. Briefly, 1.54 g N-isopropylacry-
lamide (NIPA), 26.2 mg methylene-bis-acrylamide (BIS) and 43.8 mg sodium dodecyl sulfate
(SDS) dispersed in 90 ml DI water was purged with nitrogen gas following which ammonium
persulfate (APS) and 500 μl of N,N,N,N-tetramethylethylenediamine (TEMED) were added.
The reaction was allowed to occur in a nitrogen atmosphere for 5 hours, and the particles were
purified by dialysis and collected by lyophilization. To prepare PMP porogen-based PLGA
microspheres, 0.5 ml of 0.3% w/v PMP suspension in DI water was added dropwise to 5% (w/
v) PLGA solution in chloroform. The solution was vortexed and added dropwise to a 0.1% (w/
v) PVA solution. Following overnight stirring, the particles were centrifuged and lyophilized.
PMPs were leached out of MPs by shaking the suspension at 37˚C for 2 hours. Porous particles
were separated by centrifugation at 2000 rpm for 5 min and lyophilized for further studies.
Physical characterization
Particle morphology was observed using Scanning electron microscopy (SEM, Hitachi S-
3000N, Hitachi, Pleasanton, CA). Briefly, 10 μl of the MP suspension air-dried on a coverslip
was silver sputter-coated and inserted into the SEM instrument. Additionally, the average MPs
size and pore diameter on the particles were measured from these SEM images using ImageJ
software. We considered five different images of particles to determine the particle and pore
diameter. A total of ten pores per particle surface was measured, to determine the pore diame-
ter. Two independent observers measured the pore diameters using the same technique, to
minimize observer bias. The surface charge on the particles was measured by dynamic light
scattering (DLS) as described previously [39–41].
Particle stability and degradation kinetics
To study stability of particles, the particles were dispersed in the 10% serum and incubated
for 3 days at 37˚C, and their size was evaluated at predetermined time points using DLS as
described earlier [39, 42]. Particle degradation kinetics were studied by dispersing pre-weighed
MPs in PBS and incubating while shaking at 37˚ C for 4 weeks. At predetermined time inter-
vals, the particles were collected by centrifugation (4000 rpm, 5 min), and then lyophilized.
The degradation profile was determined by calculating the residual weight of the particles over
time, compared to their initial weight at day 0.
Porous microparticles for lung tumor culture
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In vitro cell studies
For in vitro studies, the porous particles were sterilized by overnight UV light exposure fol-
lowed by immersion in 70% ethanol and washing with sterile phosphate buffered saline (PBS)
and cell culture media. Serum proteins in cell culture media were expected to be adsorbed
onto the porous MPs, which would provide a suitable surface for cell adhesion and prolifera-
tion [43]. Further, the well-plates were coated with 100 μl of 0.5% w/v agarose for all studies
associated with MPs to ensure that cells do not adhere to the bottom of the wells.
Cell attachment and viability study. To determine optimum cell seeding density on
MPs, A549 lung adenocarcinoma cells (ATCC, Manassas, VA) were seeded at varying densities
of 15, 25, 35, 45, and 55 x 104 cells per mg of particles per well of a 48 well plates. 0.2 mg of par-
ticles were added per well. The well-plates were incubated at 37˚C in alternating shaking (30
rpm, 25 mins) and static conditions (25 mins) for the first 2 hours of incubation following
which they were kept for shaking. After 24 hours, the samples were washed well with PBS to
remove unattached cells, and particles were transferred to a new 48-well plate. MTS assays
(Cell Titer96; PROMEGA, Madison, WI) were performed per manufacturer’s instructions and
absorbance was read at 490 nm using a UV-Vis spectrophotometer. A standard curve was
established with known cell numbers as described previously [44, 45], and absorbance readings
were taken at the same time as the readings for the samples. Absorbance values of the samples
were normalized against the cell standard to determine the cell number. To study the effect of
surface coating on cellular attachment and proliferation, fibronectin-coated particles were pre-
pared by sterilizing 5 mg of porous particles and placing them in 48 well plates with 5 ml of
serum-free media containing 10 μg/ml fibronectin. These particles were then shaken at 37˚C
for 2 hours at 30 rpm following which cell attachment studies were conducted as described
above. Cell attachment and viability was also visualized using Live/Dead staining (Invitrogen,
Grand Island, NY).
For the SEM procedure, the particle-cell complexes were fixed using 2.5% glutaraldehyde
followed by incubation at room temperature for 30 mins. After washing with PBS, the com-
plexes were incubated with 1% osmium tetroxide for 1 hour. The samples were again washed
and then gradually dehydrated in 50%, 75%, 95%, and 100% ethanol for 15 min. Hexamethyl-
disilazane (HMDS) was added to the samples that were then air-dried and visualized using
SEM following sputter coating.
Cell proliferation study. Cells were seeded at the optimized density of 250,000 cells per
mg of fibronectin-coated particles and were incubated by shaking at 37˚C. At pre-determined
time points (1, 3, 5, 7, and 9 days), MTS assays were carried out and the absorbance values
were normalized against a cell standard. In parallel experiments, the cells were further visual-
ized using either Live/Dead staining as mentioned above or SEM. Based on the results of in
vitro studies, PLGA-SBC particles were chosen for further investigation.
In vitro drug screening study. The therapeutic efficacies of cancer drugs were studied in
vitro using both 2D and our lung tumor cultures. In these studies, the optimized cell seeding
density of 250,000 A549 cells per mg of fibronectin-coated particles was added to agarose-
coated 48 well plates. The samples were incubated for 3 days at 37˚C to ensure cell attachment
and proliferation on the porous particles. For this study, we selected three FDA-approved lung
cancer drugs Gemcitabine, Cisplatin, and Paclitaxel [46–49] and compared their effectiveness
with three other drugs that showed higher therapeutic efficacy in preclinical trials (2D, xeno-
graft models) for lung cancer treatment but demonstrated low/no efficacy in human clinical
trials such as Doxorubicin [50], Curcumin [51], and 5-FU [52]. All drugs were added at their
previously reported IC50 concentrations: 11nM Gemcitabine [53], 4.1nM Paclitaxel [54],
64 μM Cisplatin [47], 0.6 μM Doxorubicin [55], 13 μM 5-FU [56], and 17μM curcumin [57] to
Porous microparticles for lung tumor culture
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the cell particle complexes as well as the 2D cell cultures. The samples were further incubated
for 2 days at 37˚C following which the samples were washed well to remove residual drugs.
The numbers of cell deaths in each group was tested using LDH assays (CytoTox96; PRO-
MEGA, Madison, WI, USA), following manufacturers’ directions.
Statistical analysis
The sample size used for all experiments was n = 4 unless mentioned otherwise. Statistical
analysis was performed using one-way ANOVA with StatView software (V 5.0.1, SAS Institute
Inc., Cary, NC). Values are presented as mean ± standard error. Statistical significance was
considered when p<0.05.
Results
Microparticle characterization
The physical characteristics including particle size, surface charge, and polydispersity and pore
diameter determined using ImageJ have been summarized in Table 1. The diameters of non-
porous and porous (PLGA-Gelatin, PLGA-SBC, and PLGA-PMPs) microspheres were 26, 19,
34, and 42 μm respectively. All particles had zeta potential of -19mV or higher indicating that
they are stable.
SEM images indicated that non- porous PLGA particles (Fig 1A) had a smooth spherical
surface, while PLGA-Gelatin (Fig 1B), PLGA-SBC (Fig 1C), and PLGA-PMPs (Fig 1D) micro-
spheres were spherical with distinct pores present on the surface. ImageJ analysis established
that PLGA-SBCs had an average pore diameter which was significantly larger in comparison
to pore diameters of PLGA-SBC and PLGA-gelatin MPs.
Stability and degradation kinetics
The porous MPs were further characterized and compared with non-porous PLGA MPs in
terms of their stability in media containing 10% serum. In media, all three types of particles
were relatively stable and underwent minor fluctuations by about 20–30% of their original
size, over a period of 3 days (Fig 2A). Furthermore, the degradation study conducted under
physiological conditions for 4 weeks showed that the porous microspheres using gelatin, SBC,
PMP porogens degraded 83%, 61%, and 46% of their original weight respectively, as shown in
Fig 2B. On other hand, non-porous PLGA degraded completely within 4 weeks.
Cell attachment studies
In vitro studies were conducted to optimize the cell seeding density on the MPs and to com-
pare cell binding affinity among all MPs. As shown in Fig 3A and 3B, cell attachment was satu-
rated at a seeding density of 250,000 cells/ mg of PLGA-SBC and PLGA-Gelatin MPs with or
Table 1. Initial characterization of porous particles. Five images were analyzed per formulation.
Particle type Diameter (μm) Zeta potential (mV) Pore Diameter (μm)
Non-porous PLGA 26±11 -19.3±0.3 -
PLGA-gelatin 19±5 -26.3±0.9 2.5±1.1 �
PLGA-SBC 34±13 -37.5±1.6 7.3±4.0 $
PLGA-PMPs 42±10 -22.4±1.2 1.9±0.8�
�, $ p<0.05 in comparison to pore diameter of PLGA-SBCs and PLGA-PMPs respectively
https://doi.org/10.1371/journal.pone.0217640.t001
Porous microparticles for lung tumor culture
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without fibronectin coating (Fig 3A and 3B). The fibronectin coating resulted in enhanced cell
attachment and proliferation compared to the uncoated particles. Interestingly, in the case of
PLGA-PMPs, the saturation of cell attachment occurred at 150,000 cells/ mg seeding density
(Fig 3C). No significant increase in cell attachment within each group was observed at densi-
ties >250,000 cells/ mg of MPs. When cell attachment on the different MPs at the same initial
cell seeding density (250,000 cells/ mg MPs) was studied, PLGA-SBC MPs and PLGA-PMPs
showed the highest average cell binding affinity (112,450 cells/mg and 109,372 cells/mg respec-
tively) compared to PLGA-Gelatin MPs (82,725 cells/mg of particles).
Fig 1. Morphology of porous PLGA MPs. SEM images of (A) non-porous PLGA MPs and porous MPs prepared
using (B) gelatin, (C) SBC, and (D) PMPs as porogens. The spherical morphology and porous nature of PLGA-Gelatin,
PLGA-SBC, and PLGA-PMPs can be clearly visualized.
https://doi.org/10.1371/journal.pone.0217640.g001
Fig 2. Physical characterization of porous PLGA MPs. (A) Particle stability in 10% serum indicating that non-
porous PLGA, PLGA-SBC, PLGA-Gelatin, and PLGA-PMPs maintained their diameter and granulometric properties
for 3 days. (B) Degradation of porous PLGA MPs investigated at 37˚C for 4 weeks. PLGA-Gelatin particles degraded
83% of their initial weight in 28 days while PLGA-SBC particles and PLGA-PMPs were reduced to 61% and 46% of
their original weight, respectively. The data plotted in terms of average ± standard error obtained from samples size (n)
of 3.
https://doi.org/10.1371/journal.pone.0217640.g002
Porous microparticles for lung tumor culture
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Further, cell attachment and viability (green) on our porous MPs was visualized using Live/
Dead and DAPI staining. It was observed that the cells attached onto all particles within 24
hours with minimal cell death (red) (Fig 4A). Cell attachment on the fibronectin-coated MPs
was visualized using SEM. The arrows indicate regions where the A549 cells have adhered
onto the particles. The cells appear to have retained their morphology, and appendages can be
seen indicating that the cells have spread out and begun to proliferate on the surface of all the
MPs (Fig 4B). We do not find any difference in cell morphology and cell viability among all
three MPs.
Cell proliferation study
The cell proliferation study using A549 cells indicate that cell proliferation does occur on all
three types of porous MPs, with greater cell growth observed on the porous MPs than on non-
porous MPs (Fig 5A). However significantly higher cell proliferation occurred on the surface
of porous PLGA-SBC MPs compared to proliferation on the other particles. Cell number
appeared to saturate on PLGA-gelatin and PLGA-SBC MPs by days 5 and 7 respectively, indi-
cating that the cells may not have any further surface available for proliferation. In addition,
there is significant decrease in cell proliferation on PLGA-PMPs at day 9, as these particles
have small pores, and hence oxygen and nutrient diffusion would be minimal. Our findings
concur with the Live/Dead assay, where cell death could be distinctly seen on PLGA-PMPs
and PLGA-gelatin by day 9; however, no significant cell death could be observed on
PLGA-SBC particles up to day 9 (Fig 5B).
Fig 3. Cellular adhesion onto porous MPs. A549 cell attachment on uncoated and fibronectin-coated particles for 24
hours. Maximum cell attachment was observed at 250,000 cells/mg of particles cell density for (A) PLGA-SBC and (B)
PLGA-gelatin particles. Cell attachment was saturated at 150,000 cells/mg density for (C) PLGA-PMPs. The data
plotted in terms of average ± standard error obtained from samples size (n) of 4 (� represents p-value<0.05 w.r.t cell
attachment on uncoated particles, + represents p- value<0.05 w.r.t cell attachment between different cell seeding
densities).
https://doi.org/10.1371/journal.pone.0217640.g003
Porous microparticles for lung tumor culture
PLOS ONE | https://doi.org/10.1371/journal.pone.0217640 May 31, 2019 8 / 18
In vitro drug screening
Six different drugs, namely Gemcitabine, Paclitaxel, Cisplatin, 5-FU, Curcumin, and Doxoru-
bicin, were screened in vitro for their therapeutic efficacies on 2D cell layers grown on tissue
culture polystyrene (TCPS) and tumor aggregates formed using PLGA-SBC porous MPs. Both
the cancer cell monolayer and the tumor aggregates were treated with IC50 concentrations of
all drugs based on publications. As seen in Fig 6, at the same concentration all tested chemo-
therapeutic drugs caused greater cell death on the 2D cell monolayer compared to those cul-
tured on the particles. These results confirm that A549 lung tumor cells cultured on different
substrate conditions respond differently to chemotherapy drugs.
Discussion
In this work, three types of porous PLGA MPs were prepared using different porogens, i.e.
gelatin, SBC or the novel PMPs, to choose the optimal MP formulation with surface charac-
teristics most suitable for lung cancer cell attachment and growth. Porous polymeric micro-
particle substrates have not been studied before for lung cancer cell culture in vitro. The
most important finding of this work is that PLGA-SBC porous particles which had larger,
more interconnected pores facilitated longer-term cell proliferation and viability than the
other porous models indicating that pore diameter and porosity have direct implications on
cell culture and viability on porous microparticle substrates. The lung cancer cells cultured
on PLGA-SBC microparticles showed higher drug resistance compared to the 2D model at
the same concentrations of cancer drugs, indicating that cells tend to respond differently to
treatment depending on their arrangement. This is consistent with previously published
reports comparing cell monolayers with cells cultured in a 3D format [5, 58]. Our results
Fig 4. Cellular viability on porous MPs. (A) Live/dead and DAPI stained particles after 1-day culture indicating that
the A549 lung cancer cells could attach onto the fibronectin-coated particles within 24 hours and were viable
(green = live, red = dead, Scale = 10 μm). (B) SEM images of cell attachment on PLGA-Gelatin, PLGA-SBC and
PLGA-PMPs demonstrate that the cells were clearly seen attached onto the surface of the MPs (arrows).
https://doi.org/10.1371/journal.pone.0217640.g004
Porous microparticles for lung tumor culture
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indicate the need for further investigation into PLGA-SBC porous particles-based tumor
models and validating them in vivo to find the most promising model for pharmacological
studies that will closely mimic reactions seen in vivo. We have also introduced a novel
method of forming porous MPs using PMPs. The pores of these MPs can be tailored by vary-
ing the diameters of the PMPs used.
All porous MPs developed in this work were in the diameter range of 19–42 μm, which
indicates that sufficient surface area will be available for A549 growth, since previously pub-
lished works have shown that A549 cells have an average diameter of 6–15 μm [59, 60]. The
standard deviations observed is typical of PLGA microspheres prepared using low amounts of
PVA surfactant, as observed by other groups [61–63]. Ideally, a pore diameter of 20 μm or
greater is desirable for growth and infiltration of mammalian cells, while smaller pores provide
adequate surface area for cell attachment on the surface [64, 65]. The smaller pore diameter for
PLGA-PMPs is due to the small diameter of PMP porogen, which is between 0.8 to 2.8 μm as
described previously [35]. This novel porogen was tested to obtain pores with relatively uni-
form diameters distributed throughout the MP surface to allow uniform nutrient and oxygen
diffusion. The SEM images confirm that PLGA-PMPs indeed have uniform pores of consistent
diameters, compared to the other porous MPs.
Fig 5. Cellular proliferation on porous MPs. (A) A549 cell proliferation on fibronectin-coated particles up to 9 days,
showing significantly higher cell growth on PLGA-SBC porous particles compared to the non-porous control particles
and other porous particles (PLGA-Gelatin, and PLGA-PMPs. The data plotted in terms of average ± standard error
obtained from samples size (n) of 4 (# represents p<0.05 w.r.t porous PLGA-Gelatin and PLGA-PMPs). (B) Live/Dead
staining shows A549 lung cancer cells attached on porous PLGA MPs were viable for up to 9 days with minimal cell
death. PLGA-PMPs and PLGA-Gelatin MPs showed cell death on day 9 (arrows); however, cells on PLGA-SBC MPs
remained viable throughout the study (Scale = 10 μm).
https://doi.org/10.1371/journal.pone.0217640.g005
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The physical analysis of particles in this study also involved stability and degradation kinet-
ics. The relatively unchanged sizes of all MPs suggest that they will be stable in serum and will
not undergo major aggregation or clumping during initial cell seeding, which can reduce the
surface area available for initial cell attachment and growth. It is also essential that the degrada-
tion rate of the scaffolds match the extracellular matrix deposition rate by the cells. The parti-
cles must maintain their integrity long enough for the cells to attach, proliferate and infiltrate
into them [43], and should not undergo premature degradation. Our degradation studies
show that at non-porous PLGA MPs degrade at much faster rate than its porous counterparts.
Furthermore, PLGA-Gelatin, PLGA-SBC, PLGA-PMP MPs degraded 83%, 61% and 46%
respectively of their original weight by 4 weeks. Several determinants including porosity and
particle size account for the mechanism and rate of particle degradation [66]. Generally, PLGA
degrade by hydrolysis of its ester linkages in presence of water. As these bonds are cleaved, the
acidic degraded products observed to be accumulated within non-porous particles which fur-
ther catalyze the polymer degradation itself. On other hand in MPs with open and intercon-
nected pores, these oligomers diffused out and cleared from the vicinity of microscaffolds
thereby diminishing its effect on the MPs. In support to our observation, Mittal et al, reported
to observe inverse relationship of porosity on the degradation kinetics of PLGA MPs [67]. Sim-
ilarly, Parmer et al. noted that porous microspheres resulted in 80–90% less degraded products
relative to solid microspheres of similar diameter [68]. To conclude, due to the reduced pres-
ence of acidic monomers after MP degradation, the cellular response on porous microparticles
could be superior to the smooth, non-porous ones.
Following physical characterization, the in vitro cell attachment and growth kinetics were
optimized. The optimal density of 25 x 104 cells per mg of particles observed by us concurs
with results by Sahoo et al., where the very same cell seeding density was found to demonstrate
improved MCF-7 breast cancer cell growth rate on their porous PLGA/polylactide (PLA)
microspheres [43]. Fluorescent and SEM images have also confirmed that PLGA porous parti-
cles were able to support the A549 seeding and attachment. However, it was noted that PLGA-
gelatin based microscaffolds could accommodate significantly lower number of cells than
PLGA-SBC. This might be due to its small diameter that limit the surface area available for
Fig 6. In vitro cancer drug screening. Effectiveness of chemotherapeutic drug treatment on A549 2D monolayer
grown on TCPS and porous PLGA particles was quantified using LDH assays. It was observed that cancer drugs
reduced only ~20–30% of A549 growth on the particles compared to its 2D counterparts when treated with the same
concentrations of drugs. The percentage of A549 cell death was calculated with respect to untreated cells (N/T) lysed
with triton. Data was statistically significant (n = 3, �p<0.05) when compared between two models (2D vs. particles)
for each treatment groups.
https://doi.org/10.1371/journal.pone.0217640.g006
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higher cell attachment. According to cell growth kinetics, porous microspheres promoted
higher cell attachment and growth than smooth PLGA MPs, as expected and demonstrated by
others [65, 69]. Almost two times more cells have attached and grown on porous microspheres
than non-porous microspheres which clearly indicates the advantage of having porous struc-
tures on particles. These porous network can result in particles with surface which can enhance
the cell adhesion and aid in cells to retain their natural morphology [70].
Among porous microspheres, the steady increase in cell proliferation up to 7 days observed
by us agrees with previous studies [3, 21, 70, 71]. A549 growth on PLGA-SBC and PLGA–gela-
tin was similar until day 5; however, A549 continue to proliferate more on PLGA-SBC for up
to 9 days. In case of PLGA-PMPs, A549 cells growth on these particles slowly increased over
time for up to 7 days and a reduction in growth was observed after 9 days of culture. In agree-
ment with our observation, Live/Dead assay also distinctly shows cell death on PLGA-gelatin
and PLGA-PMPs particles on day 9; and better cell viability on PLGA-SBC. Mainly, two fac-
tors may have account the limited cell growth on PLGA-gelatin and PLGA-PMPs. First the
particle diameter, the diameter of PLGA-gelatin was smaller than its other particle counter-
parts which results in lesser surface area available to the cells for attachment and proliferation.
On other hand, PLGA-PMPs’ larger surface area allowed more space for initial cell attachment,
spreading and growth. Second determinant is the pore diameter, large-diameter pores would
help in efficient transport of nutrients and metabolites to support long term cell growth on
microcarriers as noted by Lim et al [69]. Based on their study, polycaprolactone beads of pore
diameters 25–50 μm and 50–100 μm demonstrated similar growth rate of chondrocytes up to
7 days, but after that time the beads with pore diameters of 50–100 μm showed significantly
higher cell growth than those of 25–50μm. Although our porous particles have significantly
smaller pore diameters than those PCL beads, their results on the effect of pore diameter on
chondrocytes proliferation on microcarriers helps in understanding the reduced A549 growth
on PLGA-gelatin and PLGA-PMPs (pore diameters <3 μm) by day 5 and day 9 of culture
respectively than PLGA-SBCs (pore diameter>3 μm). In conclusion, the small size of particles
as in case of PLGA-gelatin and small pore diameters in both PLGA-gelatin and PLGA-PMPs
may have limited the nutrient/metabolite distribution; and thereby affected cell growth. Based
on all the studies conducted, PLGA-SBC particles comparatively aids in greater cell attach-
ment, proliferation and viability with time, than other particles.
A preliminary in vitro drug screening study was conducted on the lung tumor aggregates
developed using PLGA-SBC particles, and compared to 2D models. Our results show that
A549 cells grown on porous particles have higher resistance to chemotherapeutic drugs than
cells grown on 2D culture. In concurrence with our findings, many other research works also
reported increased drug resistance by the tumors when grown in 3D culture, than their 2D
counterparts [72–75]. Unlike 2D models, cancer cells cultured on our porous PLGA-SBCs par-
ticles eventually aggregate to forms larger spheroid-like structures (as seen in Fig 5, after 3 and
9 days of culture) which may have relevance to tumors seen in in vivo and have resulted in sim-
ilar observation with other 3D tumor models. Interactions of cancer cells with ECM protein
(like fibronectin, collagen) were reported to prevent cell apoptosis and facilitate drug resistance
[75, 76], which may have resulted in reduced cell death of A549 when cultured on fibronectin-
coated PLGA-SBS porous particles. Other factors including limited drug penetration and poor
uptake by the cells were commonly attributed to such resistance seen for tumor cells grown on
3D culture [73], may have also contributed to our observed results.
One interesting observation with the lung tumor aggregates developed using porous
PLGA-SBC microparticles was that all drugs were less potent than with 2D cell cultures. Few
previous published works, however, have shown differential drug responses between 2D and 3D
models in vitro [5, 58]. For instance, Nirmalanandhan et al. tested the effect of chemotherapeutic
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drugs on in vitro 3D spheroids prepared using A549 and H358 lung cancer cells in collagen gel
[58]. This group observed that Doxorubicin and Paclitaxel had lower therapeutic efficacy in 3D
models than that of 2D monolayers. In addition, Gemcitabine efficiently inhibited the A549
growth on 3D tumor models more than on 2D cultures, and they found no difference in potency
of Cisplatin in both cultures. The difference in cancer cell response to drug treatments may have
occurred due to the different types of tumor models used in both experiments. Zanoni et al.
investigated the potential source of variabilities that affects the reproducibility of data using
tumor models [77]. One of the factors was heterogeneous distribution of the tumor as deter-
mined based on its volume and shape. The authors proposed an approach to pre-select the
tumor spheroids such that they were homogeneous in nature, and this would prevent inconsis-
tency in drug treatments using various in vitro tumor models.
However, our design of scaffold-based lung tumor aggregates has some limitations. Our
porous particles were not porous enough to support cellular infiltration which helps in gener-
ating “three-dimensional” culture of lung cancer cells. We have utilized a simple mono-cell
cultured tumor model to carry out proof-of-concept testing of the efficacy of anti-cancer com-
pounds. Factors such as tumor architecture, interactions among cancer cells and with other
stromal cells, and an acidic tumor microenvironment are major determinants of tumor growth
in vivo [5]. In short, our lung tumor aggregates do not fully reflect the complex in vivo physio-
logical conditions as well as incorporate all distinct tumor phenotypes. Therefore, our future
studies will focus on incorporating these parameters in the development of tumor model, for
more thorough comparison of drug responses with 2D monolayers. Also, we will perform
detailed studies to validate proliferative and metabolic status of cells cultured on the porous
polymeric matrix and compare it with in vivo results. In addition, we will further optimize the
particles by increasing the pore diameter, co-culturing cancer cells with fibroblasts, adding
more detailed drug screening studies and comparing with in vivo animal models.
Besides serving as a substrate for in vitro cell cultures, porous PLGA MPs are widely utilized
to deliver therapeutics for disease treatment [78, 79] as well to transfer cells to injured tissue to
promote regeneration [as reviewed in [37]]. For instance, Lee et al. delivered mesenchymal
stem cells (MSCs) to a rat heart after myocardial infarction (MI) using polyethylenimine (PEI)
modified porous PLGA microspheres; and demonstrated an improved in vivo engraftment
rate of MSCs in infarcted myocardium than in cells alone, leading to enhanced artery blood
flow, and they also reversed the adverse cardiac remodeling after MI [80]. Qutachi et al. on the
other hand, treated porous PLGA microspheres with ethanolic sodium hydroxide solution to
form scaffold structures in body temperature to use for bone tissue engineering [81]. Such sin-
tered scaffolds offer multiscale porosity, micro- and macro porosity for cellular infiltration and
growth with desired mechanical properties to meet the tissue needs. Also, 3D cell culture mod-
els could be used to assess the toxicity of nanomaterials as an alternative experiment for in vivo
animal studies [82].
Conclusions
In summary, biodegradable porous PLGA MPs prepared using three different porogens—gela-
tin, SBC and PMPs were synthesized and compared to determine the most promising formula-
tion to be used as a substrate for in vitro lung tumor models. An innovative method of
preparing porous MPs with uniform pores, using PMPs was also presented. Although all the
three types of particles were stable and biodegradable, PLGA-SBC-based porous particles had
relatively larger pores and better interconnectivity, and favored cell attachment, growth and
viability more, and were thus chosen for further studies. Preliminary drug screening studies
conducted using PLGA-SBC particles to determine the therapeutic efficacy of various lung
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cancer drugs demonstrated that the 3D tumor model responded differently to drugs of the
same concentration, compared to the 2D cell monolayers. These results need to be confirmed
with in vivo results to determine the most appropriate and comparatively more accurate model
for future drug screening applications.
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